You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 25, 2024

Investigational Drug Information for SGN-CD19A

✉ Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug SGN-CD19A?

SGN-CD19A is an investigational drug.

There have been 4 clinical trials for SGN-CD19A. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2015.

The most common disease conditions in clinical trials are Lymphoma, Lymphoma, B-Cell, and Lymphoma, Large B-Cell, Diffuse. The leading clinical trial sponsors are Seattle Genetics, Inc., Seagen Inc., and [disabled in preview].

There are ninety US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for SGN-CD19A
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular LymphomaSeagen Inc.Phase 2
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular LymphomaSeattle Genetics, Inc.Phase 2
Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell LymphomaSeagen Inc.Phase 2

See all SGN-CD19A clinical trials

Clinical Trial Summary for SGN-CD19A

Top disease conditions for SGN-CD19A
Top clinical trial sponsors for SGN-CD19A

See all SGN-CD19A clinical trials

US Patents for SGN-CD19A

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
SGN-CD19A ⤷  Sign Up Method for the diagnosis, prognosis and treatment of lung cancer metastasis Fundacio Institut de Recerca Biomedica (IRB Barcelona) (Barcelona, ES) Institucio Catalana de Recerca I Estudis Avancats (Barcelona, ES) ⤷  Sign Up
SGN-CD19A ⤷  Sign Up Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) ⤷  Sign Up
SGN-CD19A ⤷  Sign Up Peptidomimetic macrocycles as modulators of MCL-1 AILERON THERAPEUTICS, INC. (Cambridge, MA) ⤷  Sign Up
SGN-CD19A ⤷  Sign Up Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors AbbVie Inc. (North Chicago, IL) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for SGN-CD19A

Drugname Country Document Number Estimated Expiration Related US Patent
SGN-CD19A Australia AU2013273242 2032-06-06 ⤷  Sign Up
SGN-CD19A Australia AU2019204269 2032-06-06 ⤷  Sign Up
SGN-CD19A Brazil BR112014030750 2032-06-06 ⤷  Sign Up
SGN-CD19A Canada CA2875918 2032-06-06 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.